<DOC>
	<DOCNO>NCT00004864</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Gene therapy GEM 231 may inhibit growth cancer cell make tumor sensitive chemotherapy . PURPOSE : Phase I trial study effectiveness combine docetaxel GEM 231 treat patient recurrent refractory solid tumor .</brief_summary>
	<brief_title>Docetaxel GEM 231 Treating Patients With Recurrent Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety maximum tolerate dose docetaxel GEM 231 patient recurrent refractory solid tumor . II . Determine preliminary antitumor activity GEM 231 patient population . OUTLINE : This dose escalation study GEM 231 docetaxel . Patients receive docetaxel IV 1 hour day 1 , immediately follow GEM 231 IV 2 hour day 1 , 4 , 8 , 11 . Treatment continue every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient treat escalate dos GEM 231 docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity . Patients follow monthly 3 month . PROJECTED ACCRUAL : A maximum 1 patient accrue per week study maximum tolerate dose reach .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor refractory standard therapy standard therapy exist Measurable evaluable disease No CNS metastases untreated , associated seizure , require intravenous medication and/or hospitalization PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8.5 g/dL Hepatic : Bilirubin great upper limit normal ( ULN ) , except Gilbert 's syndrome PT aPTT normal SGOT SGPT less 3 time ULN Renal : Creatinine le 1.25 time ULN No renal tubular dysfunction ( i.e. , least 2+ proteinuria within past 2 week ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month prior , , 3 month study No serious medical condition would prevent compliance No serious infection Adequate venous access No known hypersensitivity docetaxel oligodeoxynucleotides No prior peripheral neuropathy great grade 2 No psychological geographical condition would prevent compliance PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior transfusion Prior biologic therapy allow recovered No concurrent biologic therapy Chemotherapy : Prior chemotherapy allow recover No concurrent chemotherapy Endocrine therapy : Prior hormonal therapy allow recovered Concurrent palliative hormonal therapy allow Radiotherapy : Prior radiotherapy allow recover No concurrent radiotherapy ( except palliative ) Surgery : At least 2 week since prior major surgery wound complication Other : At least 2 week since prior investigational drug No investigational drug within 28 day study No concurrent CYP3A metabolism dependent drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>